Update on gene therapy Elevidys

Earlier this month the US Food and Drug Administration (FDA) requested that Sarepta Therapeutics place Elevidys clinical trials on hold, due to safety concerns. The request followed three deaths potentially related to the gene therapy products. The deaths appeared to...

NICE approves DRF-funded treatment for Duchenne

New medicine for Duchenne muscular dystrophy, funded by Duchenne Research Fund and patient groups, becomes first approved treatment in the UK for all patients with Duchenne The National Institute for Health and Care Excellence (NICE) has approved vamorolone for use on...

FDA expands approval for gene therapy Elevidys

The US Food and Drug Adminisatration has announced it has expanded the approval of Sarepta Therapeutics’ gene therapy, known as Elevidys, for the treatment of ambulatory and non-ambulatory people with Duchenne aged 4 and over. In June last year we shared that...

Vamorolone approved in the EU

The European Medicines Agency (EMA) has granted marketing authorisation for vamorolone (sold under the brand name AGAMREE) for the treatment of Duchenne in patients aged 4 years and older. It is approved for all people with Duchenne, irrespective of their underlying...

Vamorolone approved in the US

The US FDA (Food and Drug Administration) has approved Vamorolone for the treatment of Duchenne muscular dystrophy in children and adults aged 2 and over. It will be sold under the brand name Agamree and is expected to be available in the US in early 2024. This...

FDA approves first gene therapy for Duchenne

It has been a busy time in the Duchenne arena. In the US, the FDA has granted accelerated approval for the gene therapy treatment SRP-9001. This is the first time a gene therapy for Duchenne has been approved anywhere in the world, and represents a very exciting step...

Vamorolone receives Fast Track designation from FDA

We’re pleased to share news from ReveraGen, the company developing the novel steroid alternative Vamorolone (previously called VBP15), that their drug has received Fast Track designation from the FDA, which will speed up the review of Vamorolone. In 2014, Duchenne...